Clinical Trials Logo

Bipolar Disorder I clinical trials

View clinical trials related to Bipolar Disorder I.

Filter by:

NCT ID: NCT04058249 Terminated - Bipolar Disorder I Clinical Trials

Accelerated Theta Burst Stimulation for Inpatients With Bipolar Disorder

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of an accelerated schedule of theta-burst stimulation for treating manic episodes in bipolar disorder. In this open-label study, all participants will receive accelerated theta-burst stimulation.

NCT ID: NCT03822416 Completed - Schizophrenia Clinical Trials

Treating Smokers With Mental Illness

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to assist smokers in cutting back on and quitting smoking over the course of six months.

NCT ID: NCT03692910 Completed - Clinical trials for Major Depressive Episode

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

Start date: August 23, 2018
Phase: Phase 2
Study type: Interventional

This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.

NCT ID: NCT02642029 Completed - Schizophrenia Clinical Trials

Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study

Start date: February 18, 2016
Phase: N/A
Study type: Interventional

The goal of this study is to use transcranial magnetic stimulation (TMS) to investigate the impact of modulating cerebellar activity on time perception, executive function, and mood and psychotic symptoms in psychosis patients (i.e., schizophrenia, schizoaffective disorder, and bipolar disorder with psychotic features). The investigators hypothesize that abnormally reduced activity in the cerebellum contributes to the abnormalities in patients, that cerebellum-mediated disruptions in time perception may partially underlie executive dysfunction and symptoms, and that cerebellar stimulation will normalize disease-relevant outcome measures.

NCT ID: NCT01879982 Recruiting - Bipolar Disorder I Clinical Trials

PSYCHE (Personalised Monitoring SYstems for Care in Mental Health)

PSYCHE
Start date: May 2013
Phase: N/A
Study type: Observational

For the moment, the detection of a mood episode in Bipolar Disorder (BD) relies on the appearance of the first clinical signs that the clinician detect or that the patient becomes aware of and reports to the clinician. Since physiological parameters such as cardiac rhythms, respiratory rate, voice characteristics and actigraphy seem to be related to the onset of a mood episode, information collected through the combined monitoring of multiple selected physiological parameters (such as cardiac rhythms, respiratory rate, movements, voice) during wake and sleep time, using wearable user friendly systems included into garments as well as with a smartphone, may offer a new perspective in the long-term treatment of BD.